FOLD
Price
$9.19
Change
+$0.12 (+1.32%)
Updated
Feb 21 closing price
Capitalization
2.76B
73 days until earnings call
MDXG
Price
$7.98
Change
+$0.13 (+1.66%)
Updated
Feb 21 closing price
Capitalization
1.17B
3 days until earnings call
Ad is loading...

FOLD vs MDXG

Header iconFOLD vs MDXG Comparison
Open Charts FOLD vs MDXGBanner chart's image
Amicus Therapeutics
Price$9.19
Change+$0.12 (+1.32%)
Volume$2.6M
Capitalization2.76B
MiMedx Group
Price$7.98
Change+$0.13 (+1.66%)
Volume$607.7K
Capitalization1.17B
FOLD vs MDXG Comparison Chart
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. MDXG commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Hold and MDXG is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (FOLD: $9.19 vs. MDXG: $7.98)
Brand notoriety: FOLD and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 118% vs. MDXG: 103%
Market capitalization -- FOLD: $2.76B vs. MDXG: $1.17B
FOLD [@Biotechnology] is valued at $2.76B. MDXG’s [@Biotechnology] market capitalization is $1.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, MDXG is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 5 TA indicator(s) are bullish while MDXG’s TA Score has 4 bullish TA indicator(s).

  • FOLD’s TA Score: 5 bullish, 5 bearish.
  • MDXG’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, FOLD is a better buy in the short-term than MDXG.

Price Growth

FOLD (@Biotechnology) experienced а -5.94% price change this week, while MDXG (@Biotechnology) price change was -5.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

FOLD is expected to report earnings on May 07, 2025.

MDXG is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($2.76B) has a higher market cap than MDXG($1.17B). FOLD YTD gains are higher at: -2.442 vs. MDXG (-17.048). MDXG has higher annual earnings (EBITDA): 66.8M vs. FOLD (-9.2M). FOLD has more cash in the bank: 250M vs. MDXG (88.8M). MDXG has less debt than FOLD: MDXG (19M) vs FOLD (445M). FOLD has higher revenues than MDXG: FOLD (494M) vs MDXG (343M).
FOLDMDXGFOLD / MDXG
Capitalization2.76B1.17B235%
EBITDA-9.2M66.8M-14%
Gain YTD-2.442-17.04814%
P/E RatioN/A14.00-
Revenue494M343M144%
Total Cash250M88.8M282%
Total Debt445M19M2,342%
FUNDAMENTALS RATINGS
FOLD vs MDXG: Fundamental Ratings
FOLD
MDXG
OUTLOOK RATING
1..100
7659
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
9790
SMR RATING
1..100
9713
PRICE GROWTH RATING
1..100
7861
P/E GROWTH RATING
1..100
10083
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDXG's Valuation (68) in the Biotechnology industry is in the same range as FOLD (75). This means that MDXG’s stock grew similarly to FOLD’s over the last 12 months.

MDXG's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as FOLD (97). This means that MDXG’s stock grew similarly to FOLD’s over the last 12 months.

MDXG's SMR Rating (13) in the Biotechnology industry is significantly better than the same rating for FOLD (97). This means that MDXG’s stock grew significantly faster than FOLD’s over the last 12 months.

MDXG's Price Growth Rating (61) in the Biotechnology industry is in the same range as FOLD (78). This means that MDXG’s stock grew similarly to FOLD’s over the last 12 months.

MDXG's P/E Growth Rating (83) in the Biotechnology industry is in the same range as FOLD (100). This means that MDXG’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDMDXG
RSI
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
79%
View a ticker or compare two or three
Ad is loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
INVYX26.86-0.14
-0.52%
Pioneer International Equity Y
GGUPX9.72-0.07
-0.72%
Goldman Sachs Global Rl Estt Secs P
FSERX17.38-0.16
-0.91%
Franklin Real Estate Securities R6
ERSMX31.54-0.45
-1.41%
Eaton Vance Atlanta Capital SMID-Cap R
CCRIX24.22-1.13
-4.46%
Columbia Small Cap Growth R

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+1.32%
VCYT - FOLD
43%
Loosely correlated
-4.56%
ALDX - FOLD
42%
Loosely correlated
-0.45%
SRPT - FOLD
42%
Loosely correlated
-1.96%
AXON - FOLD
39%
Loosely correlated
-5.28%
MDXG - FOLD
38%
Loosely correlated
+1.66%
More

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
+1.66%
AXON - MDXG
47%
Loosely correlated
-5.28%
VCYT - MDXG
42%
Loosely correlated
-4.56%
OMER - MDXG
39%
Loosely correlated
-4.47%
ARRY - MDXG
39%
Loosely correlated
-4.49%
RAPT - MDXG
38%
Loosely correlated
-0.79%
More